Advanced pancreatic carcinoma: current treatment and future challenges
- PMID: 20101258
- DOI: 10.1038/nrclinonc.2009.236
Advanced pancreatic carcinoma: current treatment and future challenges
Abstract
Pancreatic adenocarcinoma is the most lethal of the solid tumors and the fourth leading cause of cancer-related death in North America. Most patients present with locally advanced or metastatic disease that precludes curative resection. These patients have an extremely poor prognosis. In the absence of effective screening methods, considerable efforts have been made during the past decade to identify better systemic treatments. Unfortunately most trials have not shown a survival advantage for most therapies. In tandem with this increased clinical research, there has also been an expansion of preclinical laboratory investigation. These preclinical studies revealed many of the molecular mechanisms involved in pancreatic cancer development, which has provided insights into why current therapies are ineffective. These new discoveries provide some optimism that new agents inhibiting specific targets will improve outcome and overcome the resistance of pancreatic cancer to most standard treatments. We review the current standards of care for patients with locally advanced and metastatic pancreatic carcinoma and outline some future directions for the development of new treatment strategies.
Similar articles
-
New therapeutic targets in pancreatic cancer.Cancer Treat Rev. 2019 Dec;81:101926. doi: 10.1016/j.ctrv.2019.101926. Epub 2019 Nov 11. Cancer Treat Rev. 2019. PMID: 31739115 Review.
-
A review of systemic therapy for advanced pancreatic cancer.Clin Adv Hematol Oncol. 2003 Jul;1(7):430-4. Clin Adv Hematol Oncol. 2003. PMID: 16258429 Review.
-
What treatment in 2017 for inoperable pancreatic cancers?Ann Oncol. 2017 Jul 1;28(7):1473-1483. doi: 10.1093/annonc/mdx174. Ann Oncol. 2017. PMID: 28459988 Review.
-
Current Therapeutic Options for Pancreatic Ductal Adenocarcinoma.Oncol Res Treat. 2018;41(10):590-594. doi: 10.1159/000493868. Epub 2018 Sep 28. Oncol Res Treat. 2018. PMID: 30286472 Review.
-
Management of metastatic pancreatic cancer: Current treatment options and potential new therapeutic targets.Crit Rev Oncol Hematol. 2015 Sep;95(3):318-36. doi: 10.1016/j.critrevonc.2015.03.008. Epub 2015 Apr 15. Crit Rev Oncol Hematol. 2015. PMID: 25921418 Review.
Cited by
-
Comparison of four target volume definitions for pancreatic cancer. Guidelines for treatment of the lymphatics and the primary tumor.Strahlenther Onkol. 2013 May;189(5):407-16. doi: 10.1007/s00066-013-0332-3. Epub 2013 Apr 5. Strahlenther Onkol. 2013. PMID: 23553047
-
Comprehensive Analysis of Autophagy-Associated lncRNAs Reveal Potential Prognostic Prediction in Pancreatic Cancer.Front Oncol. 2021 May 26;11:596573. doi: 10.3389/fonc.2021.596573. eCollection 2021. Front Oncol. 2021. PMID: 34123773 Free PMC article.
-
RNA sequencing of pancreatic adenocarcinoma tumors yields novel expression patterns associated with long-term survival and reveals a role for ANGPTL4.Mol Oncol. 2016 Oct;10(8):1169-82. doi: 10.1016/j.molonc.2016.05.004. Epub 2016 May 26. Mol Oncol. 2016. PMID: 27282075 Free PMC article.
-
Key drug-targeting genes in pancreatic ductal adenocarcinoma.Genes Cancer. 2021 Mar 11;12:12-24. doi: 10.18632/genesandcancer.210. eCollection 2021. Genes Cancer. 2021. PMID: 33884102 Free PMC article.
-
Pharmacokinetics of preoperative intraperitoneal 5-FU in patients with pancreatic ductal adenocarcinoma.Cancer Chemother Pharmacol. 2021 Oct;88(4):619-631. doi: 10.1007/s00280-021-04318-x. Epub 2021 Jun 16. Cancer Chemother Pharmacol. 2021. PMID: 34132895 Free PMC article.
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous